NCT06677229View on ClinicalTrials.gov

Phase 1b/2a Clinical Trial to Determine the Safety, Tolerability and Efficacy of TZ-161 in Spinal Cord Injury

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions
Acute Spinal Cord Injury (SCI)
Interventions
DRUG

Eletriptan HBr 40 mg

Oral administration of Eletriptan HBr in the form of tablets, 40 mg once daily (q.d.) for a total of 6 days, together with their usual SOC treatment.

Trial Locations (2)

Unknown

RECRUITING

Hospital Universitario Reina Sofia, Córdoba

RECRUITING

Hospital Universitario La Paz, Madrid

Sponsors

Collaborators (1)

VectorB2B
All Listed Sponsors
collaborator

VectorB2B

INDUSTRY

lead

Technophage, SA

INDUSTRY

NCT06677229 - Phase 1b/2a Clinical Trial to Determine the Safety, Tolerability and Efficacy of TZ-161 in Spinal Cord Injury | Biotech Hunter | Biotech Hunter